EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Parathyroid hormone–PTH1R signaling in cardiovascular disease and homeostasis

Dwight A Towler

Trends in Endocrinology & Metabolism · 2024-07 · 35 (7) · 648-660

DOI: 10.1016/j.tem.2024.02.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2024-07. Verfasst von Dwight A Towler. Beteiligte Einrichtung: Department of Internal Medicine - Endocrine Division, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, UT Southwestern Medic…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Homeostasis, Receptor, Parathyroid Hormone, Type 1, Parathyroid Hormone. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary hyperparathyroidism (pHPT) afflicts our aging population with an incidence approaching 50 per 100 000 patient-years at a female:male ratio of ~3:1. Decisions surrounding surgical management are currently driven by age, hypercalcemia severity, presence of osteoporosis, renal insufficiency, or hypercalciuria with or without nephrolithiasis. Cardiovascular (CV) disease (CVD) is not systematically considered. This is notable since the parathyroid hormone (PTH) 1 receptor (PTH1R) is biologically active in the vasculature, and adjusted CV mortality risk is increased almost threefold in individuals with pHPT who do not meet contemporary recommendations for surgical cure. We provide an overview of epidemiology, pharmacology, and physiology that highlights the need to: (i) identify biomarkers that establish a healthy 'set point' for CV PTH1R signaling tone; (ii) better understand the pharmacokinetic-pharmacodynamic (PK-PD) relationships of PTH1R ligands in CV homeostasis; and (iii) incorporate CVD risk assessment into the management of hyperparathyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHomeostasisReceptor, Parathyroid Hormone, Type 1Parathyroid HormoneSignal TransductionHumansHyperparathyroidism, PrimaryAnimals

Stichwörter der Autor:innen

arteriosclerosiscoronary flow reservehyperparathyroidismtachyphylaxisvascular smooth muscle phenotypic modulation

Substanzen

Receptor, Parathyroid Hormone, Type 1Parathyroid HormonePTH1R protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine - Endocrine Division, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: dwight.towler@ut…

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Towler, D. A. (2024). Parathyroid hormone–PTH1R signaling in cardiovascular disease and homeostasis. Trends in Endocrinology & Metabolism, 35(7), 648-660. https://doi.org/10.1016/j.tem.2024.02.005

Vancouver

Towler DA. Parathyroid hormone–PTH1R signaling in cardiovascular disease and homeostasis. Trends in Endocrinology & Metabolism. 2024;35(7):648-660. doi:10.1016/j.tem.2024.02.005

BibTeX
@article{Towler2024,
  author = {Towler, Dwight A},
  title = {Parathyroid hormone–PTH1R signaling in cardiovascular disease and homeostasis},
  journal = {Trends in Endocrinology & Metabolism},
  year = {2024},
  volume = {35},
  number = {7},
  pages = {648--660},
  doi = {10.1016/j.tem.2024.02.005}
}
Kostenlos starten →